Low-Dose IL-2 Dosing for Selective Treg Expansion in Type 1 Diabetes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing IL-2 therapies for autoimmune and inflammatory diseases carry the risk of activating effector T cells, exacerbating the disease due to its capacity to stimulate both regulatory and effector T cells, leading to undesirable immune responses and limited efficacy.
Innovation Solution
Administering low doses of IL-2 to selectively stimulate regulatory T cells (Tregs) without substantially inducing effector T cells (Teffs), thereby shifting the Treg/Teff balance towards Tregs, using doses of 0.05 to 3.5 MIU/day, preferably 0.1 to 2 MIU/day, with courses of 3 to 5 consecutive days followed by maintenance doses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If high dose IL-2 is administered to stimulate regulatory T cells, then the Treg population increases, but effector T cells are also activated which can exacerbate autoimmune diseases
Solution Approach 1:
The patent applies parameter changes by administering IL-2 at low doses (0.01-10 million international units per day, preferably 0.1-1 million international units per day) rather than high doses. This dose parameter modification selectively stimulates Treg expansion while avoiding Teff activation, thereby resolving the contradiction between increasing Treg population and preventing pathogenic T cell activation
Solution Approach 2:
The patent employs local quality by creating different stimulation conditions for different T cell populations through low-dose IL-2 administration. The low dose selectively affects Tregs (which have high IL-2 receptor expression and are more sensitive to low IL-2 levels) while sparing Teffs, thus achieving differential modulation of T cell subsets to resolve the contradiction
2Reliability
If IL-2 is used to treat autoimmune diseases, then immune response is modulated, but the risk of activating effector T cells increases
Solution Approach 1:
The patent changes the dosage parameter from conventional high doses to low doses (0.01-10 million international units per day). This parameter modification ensures reliable immune response modulation through Treg expansion while minimizing the harmful activation of effector T cells, thus resolving the contradiction between treatment reliability and safety
3Productivity
If conventional IL-2 doses are administered, then effector immune responses are boosted, but regulatory T cell suppression occurs
Solution Approach 1:
The patent inverts the conventional approach by using low-dose IL-2 to preferentially expand Tregs rather than Teffs. Conventional high-dose IL-2 boosts effector responses but suppresses Tregs; this patent reverses the effect by using low doses to achieve the opposite outcome - expanding Tregs while minimally affecting Teffs, thus resolving the contradiction between effector response productivity and Treg population maintenance
Data Source
Figure 1A~2D
Figure 3~4
Figure 5~7
AI summary
The present invention relates to novel therapies for treating autoimmune and inflammatory diseases. More specifically, the present invention relates to a use of low dose interleukin-2 for the treatment of type I diabetes and other autoimmune and/or inflammatory diseases.